Ro Adds Lilly’s Oral GLP-1 Foundayo to Expand Obesity Treatment Platform

New updates have been reported about Ro.

Ro has added Eli Lilly’s new oral GLP-1 drug Foundayo (orforglipron) to its obesity care platform, broadening what it positions as one of the most comprehensive GLP-1 formularies in telehealth. The once-daily pill, indicated for adults with obesity or overweight with weight-related conditions, is available to eligible Ro patients starting at a cash pay price of $149 per month for the lowest dose, plus membership fees, offering a non-injectable option that could capture demand from patients wary of injections.

Through Ro’s virtual clinic, patients can connect with licensed providers who evaluate clinical needs, insurance coverage, and cost to select among multiple FDA-approved GLP-1 therapies, including Foundayo, as either initiation or maintenance treatment. CEO and co-founder Zach Reitano framed the Lilly partnership as part of Ro’s strategy to bring new obesity drugs to market at launch and differentiate on access and flexibility, while Eli Lilly highlighted Ro’s role in reaching patients who may be deterred by stigma, access constraints, or lifestyle concerns. Ro supports both cash pay and insurance-based prescriptions with home delivery or retail pickup, and its GLP-1 Insurance Checker has already been used by more than 2 million people to verify benefits and identify the lowest-cost medication, underscoring Ro’s push to convert coverage transparency and telehealth reach into higher GLP-1 adoption and recurring revenue across its nationwide, vertically integrated care model.